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Reply to: "Is transient elastography inaccurate in chronic
hepatitis B and non-alcoholic fatty liver disease?"
To the Editor:
I appreciate the letter by Dr. Wong and colleagues on our
manuscript ‘‘Reliability of transient elastography for the detec-
tion of ﬁbrosis in non-alcoholic fatty liver disease and chronic
viral hepatitis’’ [1] because it allows me to comment more about
our results.
The manuscript aimed to describe possible factors inﬂuencing
the estimation of ﬁbrosis by transient elastography (TE) in
patients with chronic liver damage.
As is well known, elevation in serum alanine aminotransferase
(ALT) is a major confounding factor for liver stiffness measure-
ments (LSM) [2–4]. In order to analyze the accuracy of TE in
CHB and NAFLD in comparison with CHC, we excluded ‘‘a priori’’
factors known to affect TE measurement: patients with acute
liver disease, acute reactivation upon chronic liver damage, and
alcohol abuse were not included in order to avoid the inﬂuence
of acute necro-inﬂammatory edema on stiffness measurements.
Amongst 219 enrolled patients only 2 (0.9%) had ALT higher than
300 IU/L (1 CHC and 1 CHB) and 4 (0.18%) higher than 250 IU/L
(1 NAFLD, 1 CHC, 2 CHB). A stratiﬁcation of patients for ALT levels
was not available because the studied population was too homo-
geneous regarding aminotransferases. For these reasons, as
already reported in the discussion section of our manuscript,
we considered the inﬂuence of ALT on liver stiffness measure-
ment as not signiﬁcant enough in our cohort of patients.
On the other hand, our clinical observations showed that in
our patients, steatosis was a confounding factor for LSM. Com-
pared with CHC, TE was less accurate in detecting severe ﬁbrosis
in NAFLD patients, especially in those with a high degree of ste-
atosis. Fig. 4 of the paper represents the distribution of patients
with NAFLD according to ﬁbrosis and to percentage of steatosis
at biopsy vs. LSM. If we analyze this ﬁgure in detail and regroup
patients with advanced liver disease (severe ﬁbrosis/cirrhosis),
we can see that hepatic steatosis is associated with a lower
LSM within the same ﬁbrosis stage (F3–F4). Moreover, in NAFLD
patients, the stepwise multiple logistic regression analysis
showed that LSM was not an independent predictor of severe
ﬁbrosis or cirrhosis, suggesting that, in our opinion, TE is not able
to completely replace liver biopsy for the detection of ﬁbrosis in
NAFLD.
Different results reported by Wong and others from Oriental
areas [5,6] have to be interpreted while considering that the
features of the metabolic syndrome and the clinical correlates
are different from European ones. However, these different
results support the concept that different steatosis features may
have signiﬁcant inﬂuences on LSM.
In conclusion our work conﬁrmed the reliability of Fibroscan
for evaluating liver ﬁbrosis in CHB or NAFLD patients, but it also
describes some limitations to be taken into account in such cate-
gories of patients. Although the correlation between LSM and
ﬁbrosis stage was demonstrated, its sensibility and speciﬁcity
were lower in CHB and NAFLD with respect to CHC patients. This
work helps the physician to interpret, in a proper manner, Fibro-
scan results in CHB and NAFLD patients with possible liver stea-
tosis or other confounding factors such as high BMI, elder age or
high ALT values.
Conﬂict of interest
The author declared she does not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the
detection of ﬁbrosis in non-alcoholic fatty liver disease and chronic viral
hepatitis. J Hepatol 2011;54:64–71.
[2] Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness
values measured by transient elastography. Hepatology 2008 Feb;47 (2):
380–384.
[3] Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate
marker of liver ﬁbrosis inﬂuenced by major changes of transaminases. J Viral
Hepat 2007 May;14 (5):360–369.
[4] Chan HLY, Wong GLH, Choi PCL, et al. Alanina aminotransferase-based
algorithms of liver stiffness measurement by transient elastography (Fibro-
scan) for liver ﬁbrosis in chronic hepatitis B. J Vir Hepat 2008;16:36–44.
[5] Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver
ﬁbrosis by measurement of stiffness in patients with nonalcoholic fatty liver
disease (NAFLD). Dig Liver Dis. 2008;40:371–378.
[6] Wong VW, Vergniol J, Wong GL, et al. Diagnosis of ﬁbrosis and cirrhosis using




San Giovanni Battista of Turin,
Turin, Italy
Letters to the EditorNon-invasive prediction of ﬁbrosis in non-alcoholic fatty liver diseaseTo the Editor:
Non-alcoholic fatty liver disease (NAFLD) is one of the most com-
mon causes of liver disease worldwide. It includes a wide spec-
trum of liver diseases, ranging from pure steatosis to
nonalcoholic steatohepatitis (NASH), and eventually to liver cir-498 Journal of Hepatology 2rhosis with its complications. The accurate evaluation of liver
ﬁbrosis in patients with NAFLD is important to identify patients
who may develop complications. The liver biopsy is still the best
available standard in the assessment of liver ﬁbrosis. However,
liver biopsy has limitations due to invasiveness, small tissue011 vol. 55 j 497–501
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samples, and inter- and intra-observer error. For this reason, sev-
eral simple non-invasive clinical scoring systems have been pro-
posed to diagnose advanced ﬁbrosis in NAFLD [1].
We read with great interest the article by Rufﬁllo et al. that
compares the NAFLD ﬁbrosis score and BARD score in predicting
ﬁbrosis in NAFLD [2]. In their retrospective analysis, they con-
cluded that both scoring systems were similar in NAFLD. The
results are interesting and likely to contribute to our understand-
ing of this issue; however, we have some concerns about the data
presented by the authors.
Firstly, as mentioned in the text, the presence of impaired
fasting glucose (IFG) or diabetes mellitus (DM) is a component
of the NAFLD ﬁbrosis score. Although it was stated in the article
that some of the patients were diabetic at baseline, there is no
information regarding the glucose tolerance status of the other
subjects. It is well known that NAFLD is strongly associated with
obesity, hypertension, dyslipidemia and also glucose tolerance
abnormalities [3,4]. In addition, all these metabolic problems
are risk factors for DM and also prediabetes, namely IFG and
impaired glucose tolerance (IGT). In light of these data, we think
that some of the study participants may still have overt glucose
dysregulation or DM without implementation of the glucose tol-
erance test. Secondly, no information about the medications was
given in the text. Yet, we know that liver enzymes are easily
affected by medications started for the metabolic problems men-
tioned above [5,6]. This issue is important because AST/ALT ratio
is another variable in the NAFLD ﬁbrosis score.
We conclude that the presence of major confounders raises
some questions about the data presented, and as such some of
the resulting interpretations should be taken with caution. In
such a case, statistical correlations may also be misleading. It
would be appreciated if the authors could present some more
data adjusted for the topics mentioned above. This could provide
the readers of the journal clearer information in the prediction of
ﬁbrosis by NAFLD ﬁbrosis score in this clinically relevant
condition.Reply to: "Non-invasive pr
nonalcoholic fatty
To the Editor:
We would like to address the concerns presented by Dr. Dogru
et al. in their letter to the Editor. The ﬁrst issue commented on
pertains to one of the six variables included in the formula of
the NAFLD ﬁbrosis score: impaired fasting glucose/diabetes.
For that variable, we took the same deﬁnition from the original
paper by Angulo et al. [1]. Diabetes was deﬁned as a fasting
glucose levelP126 mg/dl or a patient who was already under
treatment with anti-diabetic drugs; and impaired fasting glu-
cose, as a fasting glucose levelP110 mg/dl. We did not perform
any glucose tolerance test in our patients. As stated in our
paper [3], we just retrospectively analyzed data of consecutive
patients with biopsy proven NAFLD that had been prospectively
collected. One advantage of both, the NAFLD ﬁbrosis score and
the BARD score [2], is that they include 6 and 3, respectively,
easily available variables. Being a group that is especially inter-
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ested in research on NAFLD, we had all of these variables avail-
able in our database. In fact, at present if we wanted to repeat
the analysis of comparison between both scoring systems, data
on 182 biopsy proven NAFLD patients would be available
(instead of 138 in our published paper).
The second concern raises the point about the lack of
information on medications that patients could be receiving.
We agree that some drugs may inﬂuence the serum levels
of aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) and we do not have the complete information
about medications taken by our patients. Some of them were
receiving antihypertensive drugs such as enalapril, or antihy-
perlipidemic drugs such as statins. However, the pattern of
liver enzymes in our NAFLD patients conformed to those
commonly found; with a mild to moderate elevation and an
ALT predominance. Median ALT was 69 IU/L, interquartile
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